Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.50 |
| ▸ | CCR8 | P51685 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21591890 | 0.83 | SMN1; SMN2 (0.44) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL9182724 | 0.83 | SMN1; SMN2 (0.44) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL29362546 | 0.83 | SMN1; SMN2 (0.44) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL15960727 | 0.80 | TLR8 (0.45) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL1496306 | 0.80 | KMT5B (0.46) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL5536166 | 0.80 | ATAD2 (0.41) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL6002911 | 0.80 | TLR8 (0.43) | CCR1CCR5CCR8KDM4ENPC1 | |
| SCHEMBL5233653 | 0.80 | SMN1; SMN2 (0.49) | CCR1CCR5CCR8SMN1; SMN2KDM4E | |
| SCHEMBL12503594 | 0.80 | PDGFRB (0.47) | CCR1CCR5CCR8EGFR | |
| SCHEMBL11332805 | 0.79 | ALDH1A1 (0.50) | CCR1CCR5CCR8SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20180053868-A1 | PHOTOELECTRIC CONVERSION DEVICE HAVING REFLECTION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-22 | — | — | US | disclosed |
| US-20180053868-A1 | PHOTOELECTRIC CONVERSION DEVICE HAVING REFLECTION PLATE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-22 | — | — | US | disclosed |
| US-20170162808-A1 | PHOTOELECTRIC CONVERSION DEVICE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20170162808-A1 | PHOTOELECTRIC CONVERSION DEVICE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160372675-A1 | MACROMOLECULAR COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-22 | — | — | US | disclosed |
| US-9512149-B2 | Reactive compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9512149-B2 | Reactive compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9472763-B2 | Macromolecular compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-8142908-B2 | Polymer light-emitting material comprising a conjugated polymer and compound exhibiting light emission from the triplet excited state and polymer light-emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20120008068-A1 | POLYMER COMPOUND AND POLYMER LIGHT-EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-8012603-B2 | Polyanilines; strong fluorescence and large charge transporting properties | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20080138651-A1 | Polyanilines; strong fluorescence and large charge transporting properties | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080118773-A1 | Complex Composition, Polymer Complex Compound And Polymer Light-Emitting Device | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-05-22 | — | — | US | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080003422-A1 | Polymer Compound, Polymer Thin Film and Polymer Thin Film Device Using the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20070103059-A1 | Composition and polymer light-emitting device | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070051922-A1 | Polymer light-emitting material and polymer light-emitting device | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070040164-A1 | Polymer complex compound and polymer light emitting device using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | CCR1 141/4885CCR5 334/4885CCR8 363/4885 |
| US-20080138651-A1 | Polyanilines; strong fluorescence and large charge transporting properties | BRS3, SLC43A1, MRPS23 | CCR1 70/4885CCR5 521/4885CCR8 403/4885 |
| US-20160372675-A1 | MACROMOLECULAR COMPOUND | EXOSC4, TRPC6, MRPS22 | CCR1 288/4885CCR5 2067/4885CCR8 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.